Results 31 to 40 of about 85,538 (123)

A Hybrid Retroperitoneal-Transperitoneal Approach for Robot-Assisted Radical Nephrectomy: A Technical Report of Two Cases. [PDF]

IJU Case Rep
ABSTRACT Introduction Robot‐assisted radical nephrectomy (RARN) can be performed using either transperitoneal or retroperitoneal approaches; however, each has inherent limitations, particularly in cases with complex hilar anatomy or post‐systemic therapy fibrosis.
Ohzeki T, Mitsuhashi Y, Inoki L, Morita T, Hayashi T, Nishioka T, Fujimoto S, Fujita K.   +7 more
europepmc   +2 more sources

Oligoprogressive renal cell carcinoma: What is the role of surgery? [PDF]

BJU Int
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Re C, Ince WHJ, Bickley L, Blackmur JP, Ismail MH, Kyeremeh J, Kuusk T, Serrao EM, Jones JO, Stewart GD.   +9 more
europepmc   +2 more sources

Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN). [PDF]

Clin Genitourin Cancer
In this study we evaluated outcomes of patients with metastatic renal cell carcinoma who received immunotherapy before surgery. We found that receiving immunotherapy combinations before surgery can offer patients benefits in reducing tumor size and improving disease control.Immunotherapy (IO) has improved outcomes for patients with metastatic renal ...
Gunenc D, Issa W, Gerald T, Zhou Q, Zhang S, Ibezue IC, Bhanvadia R, Tachibana I, Brugarolas J, Hammers H, Qin Q, Kapur P, Woldu S, Gaston K, Lotan Y, Cadeddu J, Wang AZ, Margulis V, Zhang T.   +18 more
europepmc   +4 more sources

Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. [PDF]

Transl Cancer Res, 2019
Editorial comment on the article: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical ...
Minervini A, Mari A, Di Maida F, Campi R, Carini M, Lapini A.   +5 more
europepmc   +4 more sources

Real-world drivers of treatment choices in synchronous metastatic renal cell carcinoma. [PDF]

BJUI Compass
Abstract Objectives This study aimed to identify clinical and socioeconomic factors associated with treatment selection and survival in patients diagnosed with synchronous metastatic renal cell carcinoma (mRCC). Patients and Methods The Renal Cell Cancer Database Sweden (RCCBaSe2.0), linking the National Swedish Kidney Cancer Register with other ...
Almdalal T, Fahlén M, Harmenberg U, Ljungberg B, Lindskog M.   +4 more
europepmc   +2 more sources

Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab

Japanese Journal of Clinical Oncology, 2022
Abstract Objectives To explore the therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Patients and methods Forty-one patients with ...
Maki Yoshino, Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Koichi Nishimura, Hidekazu Tachibana, Hironori Fukuda, Daisuke Toki, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo, Toshio Takagi   +15 more
openaire   +2 more sources

Editorial Comment: Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. [PDF]

Int Braz J Urol, 2020
Zequi SC.
europepmc   +3 more sources

Deferred Versus Upfront Cytoreductive Nephrectomy in MetaStatic Renal Cell Carcinoma: Comparative Survival Analysis in the Immunotherapy Era. [PDF]

Cancers (Basel)
Background: The optimal timing of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) remains a subject of debate, particularly in the immunotherapy era. This study compares survival outcomes between deferred CN (dCN) and upfront CN (uCN) in mRCC patients receiving modern immunotherapy regimens in the real-world setting.
Xu T, Tuerxun P, Liu N, Ji C, Zhao K, Qian Y, Abudushataer A, Li Y, Jiang X, Xiong Z, Wang M, Jia R, Ge YZ.   +12 more
europepmc   +3 more sources

Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma

, 2020
We reassessed the effect of cytoreductive nephrectomy on survival in a population-based contemporary clear-cell metastatic renal cell carcinoma (ccmRCC) cohort.
Mistretta F. A., Briganti A., Saad F., Kapoor A., Knipper S., Simeone C., Karakiewicz P. I., Pecoraro A., Tian Z., Berruti A., Dzyuba-Negrean C., Antonelli A., Shariat S. F., Palumbo C.   +13 more
core   +2 more sources

Cytoreductive nephrectomy in the era of targeted therapies: a review [PDF]

, 2017
In the pre-targeted therapy era, palliative cytoreductive nephrectomy combined with cytokine immunotherapy was the standard treatment protocol for the management of metastatic renal cell carcinoma.
Prokar Dasgupta, Rick Catterwell, Catterwell, Rick, Dasgupta, Prokar, Nisha Pindoria, Gideon Blecher, Pindoria, Nisha, Nicholas Raison, Raison, Nicholas, Blecher, Gideon   +9 more
core   +1 more source